ABSTRACT NUMBER: 5L

Rapamycin Vs. Placebo for the Treatment of Inclusion Body Myositis: Improvement of the 6 Min Walking Distance, a Functional Scale, the FVC and Muscle Quantitative MRI

Olivier Benveniste1, Jean-Yves Hogrel2, Melanie Annoussamy2, Damien Bachasson2, Aude Rigolet3, Laurent Servais2, Joe-Elie Salem4, Baptiste Hervier3, Oceane Landon Cardinal5, Kuberaka Mariampillai1, Jean-Sebastien Hulot4, Pierre Carlier2 and Yves Allenbach6, 1Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, 2Institute of Myology, Paris, France, 3Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, 4INSERM, CIC-1421, Paris, France, 5Internal Medicine, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France, 6Internal Medicine, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: October 19, 2017

Keywords: Late-Breaking 2017, Myositis

SESSION INFORMATION

Date: Tuesday, November 7, 2017
Session Title: ACR Late-Breaking Abstract Session
Session Type: ACR Late-breaking Abstract Session
Session Time: 4:30PM-6:00PM

Background/Purpose:

Inclusion body Myositis (IBM) is the most frequent myositis in patients over 50 years old. Conventional immunosuppressive drugs are today ineffective or even aggravate muscle deficits. Rapamycin is a mTOR inhibitor used in organ transplantation. Potentially, rapamycin can deplete T effector cells, preserve T regulatory cells and induce autophagy (protein degradation), all parameters impaired during IBM.

Methods:

RAPAMI is a prospective, randomized, controlled, double blind, monocentric, phase IIb trial evaluating the efficacy of rapamy cin against placebo (NCT02481453). The primary endpoint was stabilization of maximal voluntary quadriceps isometric strength assessed with a dynamometer (Biodex System3 pro). Secondary endpoints included safety, other muscle groups strength, distance walked in 6 minutes (6MWD), pulmonary functional tests, functional scales, and muscle quality assessed by quantitative nuclear resonance magnetic exams (NRM).

Results:

Forty-four patients were treated by oral rapamycin (2 mg/d, n=22) or placebo (n=22) during 12
Forty-four patients were treated by oral rapamycin (2 mg/d, n=22) or placebo (n=22) during 12 months (M12). Twelve months after the initiation of the treatment, the quadriceps strength decreased significantly and similarly in both groups (mean relative change: -11.07% vs. -12.36%). Nevertheless, in comparison to the placebo group, 6MWD was unchanged (mean change: -4.1 m vs. -38.5 m, p=0.035), IBM weakness composite index was less degraded (11.91% vs. 24.26%, p=0.038) and forced vital capacity significantly improved (mean relative change: +12.3% vs. 1.6%, p=0.016). Additionally, NRM showed significant less fat muscle replacement (difference between M12 and baseline in %) in quadriceps (1.7 vs. 4.4, p=0.025) or hamstrings (0.9 vs. 7.3, p=0.027). Finally in NRM, the loss between M12 and baseline of contractile cross-sectional area (mm²) was less pronounced in quadriceps (-3.7 vs. -10.7, p=0.005).

Conclusion: Even if the primary endpoint was not reached, these first results showed coherent data in favor of rapamycin. Notably for the first time in a RCT, an improvement of the 6MWD is observed during IBM.

Disclosure: O. Benveniste, None; J. Y. Hogrel, None; M. Anoussamy, None; D. Bachasson, None; A. Rigolet, None; L. Servais, None; J. E. Salem, None; B. Hervier, None; O. Landon Cardinal, None; K. Mariampillai, None; J. S. hulot, None; P. Carlier, None; Y. Allenbach, None.

To cite this abstract in AMA style:
